Peters, S., Pujol, J., Dafni, U., Domine, M., Popat, S., Reck, M., . . . Collaborators, E. 4. S. (2022). Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.
Citación estilo ChicagoPeters, S., et al. Consolidation Nivolumab and Ipilimumab Versus Observation in Limited-disease Small-cell Lung Cancer After Chemo-radiotherapy - Results From the Randomised Phase II ETOP/IFCT 4-12 STIMULI Trial. 2022.
Cita MLAPeters, S., et al. Consolidation Nivolumab and Ipilimumab Versus Observation in Limited-disease Small-cell Lung Cancer After Chemo-radiotherapy - Results From the Randomised Phase II ETOP/IFCT 4-12 STIMULI Trial. 2022.